Silence Therapeutics (SLN) Current Assets (2018 - 2026)

Silence Therapeutics has disclosed Current Assets across 9 years of filings, most recently posting $102.9 million for Q1 2026.

• Current Assets for Q1 2026 came in at $102.9 million, down 39.42% year-over-year; the trailing twelve-month figure through Mar 2026 was $102.9 million (down 39.42% YoY), and the FY2025 annual result was $118.7 million, down 36.67% from the prior year.
• Current Assets came in at $102.9 million for Q1 2026 at Silence Therapeutics, down from $118.7 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $187.4 million in Q4 2024 to a low of $100.6 million in Q4 2023.
• The 5-year median for Current Assets is $126.1 million (2025), against an average of $134.4 million.
• Across the five-year window, Current Assets surged 86.32% in 2024 and slumped 39.42% in 2026, its largest moves.
• Silence Therapeutics' Current Assets stood at $113.4 million in 2022, then dropped by 11.33% to $100.6 million in 2023, then soared by 86.32% to $187.4 million in 2024, then slumped by 36.67% to $118.7 million in 2025, then decreased by 13.32% to $102.9 million in 2026.
• The last three Current Assets figures came in at $102.9 million (Q1 2026), $118.7 million (Q4 2025), and $133.6 million (Q3 2025), per Business Quant data.